Helicobacter PyloriNCT00466700
Helicobacter in The Gambia (Part 1)
An observational study of Helicobacter Pylori, run by Medical Research Council Unit, The Gambia at 1 site in The Gambia.
Trial summary
H. pylori infection causes the stomach to become inflamed. The problem usually begins in childhood and leads to stomach problems in adult life. Study participants will be residents of The Gambia, West Africa, and will be studied at the Medical Research Council of Great Britain facility in Fajara, The Gambia. Read more about this study
- Who is it for?
- Ages 6 months and older
- Conditions the study is for
- Helicobacter Pylori
- How many people
- 75 participants
- Where
- 1 siteThe Gambia
- Study dates
- Jul 2007to Mar 2009
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 6 months and older
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: The study population will consist of rural subsistence farmers and semi-urban dwellers attending the clinic at the MRC research laboratories in Fajara, The Gambia. The study will be comprised of subjects who are undergoing endoscopy for diagnostic purposes within the endoscopy unit at Fajara.
Who may be able to join
- Adult Subjects: All consenting subjects referred for diagnostic upper endoscopy to the Medical Research Council (MRC) unit in Fajara will be eligible for inclusion, provided none of the exclusion criteria apply. In The Gambia, subjects aged 18 years and above are considered as adult. Subjects will be sampled only once.
- Child Subjects: All subjects under 2 years of age referred for diagnostic upper endoscopy to the MRC unit in Fajara will be eligible for inclusion, provided their parents give informed consent and that none of the exclusion criteria apply. The minimum cut-off age for this study will be 6 months.
Who cannot join
- Adult Subjects: Any contraindication to endoscopy and biopsy, such as as liver dysfunction, history of bleeding, history of other serious organ disease (for example, kidney, heart, lung), bleeding time prolonged to over 10 minutes, or unexpected findings such as esophageal or gastric stricture that limits endoscopic examination will exclude subjects from the study, as will the use of antibiotics during the previous 2 weeks. Specific tests such as bleeding times will be performed at the discretion of the supervising clinician, who is undertaking the diagnostic endoscopy for the subject's clinical benefit. In addition, if the endoscopist feels that prolonging the procedure by 2 or 3 minutes in order to take the research biopsies would not be advisable for any reason, the subject will be excluded from the study.
- Child Subjects: Any contraindication to endoscopy and biopsy, such as as liver dysfunction, history of bleeding, history of other serious organ disease (for example, kidney, heart, lung), bleeding time prolonged to over 10 minutes, or unexpected findings such as esophageal stricture that limits endoscopic examination will exclude subjects from the study, as will the use of antibiotics during the previous 2 weeks. In addition, if the endoscopist feels that prolonging the procedure by 2 or 3 minutes in order to take the research biopsies would not be advisable for any reason, the subject will be excluded from the study. Specific tests such as bleeding times will be performed at the discretion of the supervising clinician, who is undertaking the diagnostic endoscopy for the subject's clinical benefit.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Genotypes of Helicobacter Pylori in West African Children and Adults: Part 1: The Development and Evaluation of Minimally Invasive Techniques for Obtaining H. Pylori Isolates From Adults and Children in The Gambia
- pylori infection causes the stomach to become inflamed. The problem usually begins in childhood and leads to stomach problems in adult life. Study participants will be residents of The Gambia, West Africa, and will be studied at the Medical Research Council of Great Britain facility in Fajara, The Gambia. Up to 75 adults 18 years and older and 20 malnourished children 6 months to 2 years of age, who are undergoing endoscopy as part of their medical care, will be studied. (Endoscopy is when a thin, lighted device is used to look inside the body.) During this study procedure, tiny pieces of tissue, called biopsies, will be taken from the stomach and checked for H. pylori infection. Participants found to be infected will be given antibiotic treatment. Participation in the study will last approximately 72 hours.
Read the detailed description
The overall goal in this pilot project is to implement and evaluate a new method for isolating Helicobacter pylori (H. pylori) strains from young children, and to compare these isolates with those obtained from adults from the same population. This is part I of the study, and part II is described in the Division of Microbiology and Infectious Diseases protocol 06-0004. The transition from childhood colonization to adult disease state may be affected by multiple factors including evolution of genotypes of colonizing H. pylori strains themselves, driven in part by the host response to infection. The hypothesis is that H. pylori strains from Gambian children will differ genetically from the strains of chronically colonized adults from the same community. Genetic and phenotypic characterization of pediatric and adult H. pylori isolates will test for fundamental differences between strains circulating in these 2 age groups, and thereby help evaluate the importance of strain selection and/or genome evolution in such high risk societies. Specific objectives are: to compare the range of genotypes obtained from H. pylori cultured from gastric biopsies from Gambian adults and children undergoing diagnostic upper endoscopy, with those obtained by culture of gastric juice aspirates from the same subjects. This will allow interpretation of results obtained from culture of nasogastric aspirates from children who do not require diagnostic endoscopy, when compared to gastric biopsy-derived H. pylori isolates. Most genotyping will entail polymerase chain reaction tests for virulence markers, limited (focused) DNA sequencing, and tests for susceptibility to metronidazole and frequency of forward mutation. The study population will consist of residents of The Gambia, West Africa. Up to seventy five adults of both sexes and all ages, who are undergoing diagnostic endoscopy as part of their clinical management, and 20 malnourished children of both sexes and less than 2 years of age, who are undergoing diagnostic endoscopy as part of their clinical management, will be studied. All subjects will be studied at the Medical Research Council of Great Britain research laboratories and clinical facility in Fajara, The Gambia. The main outcome measure will be the degree of relatedness between bacterial isolates. This will be assessed by visual comparison between random amplification of polymorphic DNA (RAPD) results, by comparison of genotype for alleles of interest, and definitively by sequencing of housekeeping genes to construct phylogenetic trees of relatedness, using the STAR program (a computer program for putting DNA sequences together for analysis) and multiple locus sequence typing (MLST) database. There are no outcome measures for human subjects. All laboratory investigations will be conducted upon bacterial isolates.
- Conditions
- Helicobacter Pylori
- Keywords
- Helicobacter pylori, Gambia, endoscopy, Africa
What is being measured
The primary outcome is the main question the study is designed to answer.
The degree of relatedness between bacterial isolates
This will be assessed by visual comparison between RAPD results, by comparison of genotypes for alleles of interest, and definitively by sequencing of housekeeping genes to construct phylogenetic trees of relatedness, using the STAR program (a computer program for putting DNA sequences together for analysis) and MLST database.
There are no outcome measures for human subjects. All laboratory investigations will be conducted upon bacterial isolates There are no outcome measures for human subjects. All laboratory investigations will be conducted upon bacterial isolates
Measured: 4 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Apr 2007 (estimated)
- Study startJul 2007
- Primary completionJun 2008
- Study completionMar 2009
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Helicobacter PyloriStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Prospective
- Enrolment
- 75 participants (actual)
Sponsor and investigators
- Lead sponsor
- Medical Research Council Unit, The Gambia
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Richard Adegbola, PhD, FRCPath, Principal investigator, Medical Research Council Unit, The Gambia
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00466700
- Sponsor's protocol ID
- 06-0053
- Status last verified
- May 2015
- First submitted
- 26 Apr 2007
- Last updated
- 8 May 2015
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 8 May 2015. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Genotypes of Helicobacter Pylori in West African Children and Adults: Part 1: The Development and Evaluation of Minimally Invasive Techniques for Obtaining H. Pylori Isolates From Adults and Children in The Gambia
- ClinicalTrials.gov ID
- NCT00466700
- Acronym / sponsor ID
- 06-0053
- Conditions
- Helicobacter Pylori
- Keywords
- Helicobacter pylori, Gambia, endoscopy, Africa
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 75 participants (actual)
- Lead sponsor
- Medical Research Council Unit, The GambiaUniversity, hospital or other
- Collaborators
- National Institute of Allergy and Infectious Diseases (NIAID)
- Study start
- Jul 2007
- Primary completion
- Jun 2008 (actual)
- Study completion
- Mar 2009 (actual)
- First posted
- 27 Apr 2007 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
- pylori infection causes the stomach to become inflamed. The problem usually begins in childhood and leads to stomach problems in adult life. Study participants will be residents of The Gambia, West Africa, and will be studied at the Medical Research Council of Great Britain facility in Fajara, The Gambia. Up to 75 adults 18 years and older and 20 malnourished children 6 months to 2 years of age, who are undergoing endoscopy as part of their medical care, will be studied. (Endoscopy is when a thin, lighted device is used to look inside the body.) During this study procedure, tiny pieces of tissue, called biopsies, will be taken from the stomach and checked for H. pylori infection. Participants found to be infected will be given antibiotic treatment. Participation in the study will last approximately 72 hours.
Detailed description
The overall goal in this pilot project is to implement and evaluate a new method for isolating Helicobacter pylori (H. pylori) strains from young children, and to compare these isolates with those obtained from adults from the same population. This is part I of the study, and part II is described in the Division of Microbiology and Infectious Diseases protocol 06-0004. The transition from childhood colonization to adult disease state may be affected by multiple factors including evolution of genotypes of colonizing H. pylori strains themselves, driven in part by the host response to infection. The hypothesis is that H. pylori strains from Gambian children will differ genetically from the strains of chronically colonized adults from the same community. Genetic and phenotypic characterization of pediatric and adult H. pylori isolates will test for fundamental differences between strains circulating in these 2 age groups, and thereby help evaluate the importance of strain selection and/or genome evolution in such high risk societies. Specific objectives are: to compare the range of genotypes obtained from H. pylori cultured from gastric biopsies from Gambian adults and children undergoing diagnostic upper endoscopy, with those obtained by culture of gastric juice aspirates from the same subjects. This will allow interpretation of results obtained from culture of nasogastric aspirates from children who do not require diagnostic endoscopy, when compared to gastric biopsy-derived H. pylori isolates. Most genotyping will entail polymerase chain reaction tests for virulence markers, limited (focused) DNA sequencing, and tests for susceptibility to metronidazole and frequency of forward mutation. The study population will consist of residents of The Gambia, West Africa. Up to seventy five adults of both sexes and all ages, who are undergoing diagnostic endoscopy as part of their clinical management, and 20 malnourished children of both sexes and less than 2 years of age, who are undergoing diagnostic endoscopy as part of their clinical management, will be studied. All subjects will be studied at the Medical Research Council of Great Britain research laboratories and clinical facility in Fajara, The Gambia. The main outcome measure will be the degree of relatedness between bacterial isolates. This will be assessed by visual comparison between random amplification of polymorphic DNA (RAPD) results, by comparison of genotype for alleles of interest, and definitively by sequencing of housekeeping genes to construct phylogenetic trees of relatedness, using the STAR program (a computer program for putting DNA sequences together for analysis) and multiple locus sequence typing (MLST) database. There are no outcome measures for human subjects. All laboratory investigations will be conducted upon bacterial isolates.
Study design
- Observational model
- Case only
- Time perspective
- Prospective
Who may qualify
- Ages
- 6 months and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- The study population will consist of rural subsistence farmers and semi-urban dwellers attending the clinic at the MRC research laboratories in Fajara, The Gambia. The study will be comprised of subjects who are undergoing endoscopy for diagnostic purposes within the endoscopy unit at Fajara.
Key inclusion criteria (2 listed)
- Adult Subjects: All consenting subjects referred for diagnostic upper endoscopy to the Medical Research Council (MRC) unit in Fajara will be eligible for inclusion, provided none of the exclusion criteria apply. In The Gambia, subjects aged 18 years and above are considered as adult. Subjects will be sampled only once.
- Child Subjects: All subjects under 2 years of age referred for diagnostic upper endoscopy to the MRC unit in Fajara will be eligible for inclusion, provided their parents give informed consent and that none of the exclusion criteria apply. The minimum cut-off age for this study will be 6 months.
Key exclusion criteria (2 listed)
- Adult Subjects: Any contraindication to endoscopy and biopsy, such as as liver dysfunction, history of bleeding, history of other serious organ disease (for example, kidney, heart, lung), bleeding time prolonged to over 10 minutes, or unexpected findings such as esophageal or gastric stricture that limits endoscopic examination will exclude subjects from the study, as will the use of antibiotics during the previous 2 weeks. Specific tests such as bleeding times will be performed at the discretion of the supervising clinician, who is undertaking the diagnostic endoscopy for the subject's clinical benefit. In addition, if the endoscopist feels that prolonging the procedure by 2 or 3 minutes in order to take the research biopsies would not be advisable for any reason, the subject will be excluded from the study.
- Child Subjects: Any contraindication to endoscopy and biopsy, such as as liver dysfunction, history of bleeding, history of other serious organ disease (for example, kidney, heart, lung), bleeding time prolonged to over 10 minutes, or unexpected findings such as esophageal stricture that limits endoscopic examination will exclude subjects from the study, as will the use of antibiotics during the previous 2 weeks. In addition, if the endoscopist feels that prolonging the procedure by 2 or 3 minutes in order to take the research biopsies would not be advisable for any reason, the subject will be excluded from the study. Specific tests such as bleeding times will be performed at the discretion of the supervising clinician, who is undertaking the diagnostic endoscopy for the subject's clinical benefit.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
The degree of relatedness between bacterial isolates
Time frame: 4 years
This will be assessed by visual comparison between RAPD results, by comparison of genotypes for alleles of interest, and definitively by sequencing of housekeeping genes to construct phylogenetic trees of relatedness, using the STAR program (a computer program for putting DNA sequences together for analysis) and MLST database. There are no outcome measures for human subjects. All laboratory investigations will be conducted upon bacterial isolates There are no outcome measures for human subjects. All laboratory investigations will be conducted upon bacterial isolates
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 May 2015.
Related trials for Helicobacter Pylori
Not yet recruiting
Pilot Study of a Gastric String Test Combined With a Rapid Antigen Assay for Helicobacter Pylori Detection
Helicobacter Pylori
RecruitingPhase 3
Keverprazan-Minocycline Dual Therapy of Different Durations Versus Bismuth Quadruple Therapy for Helicobacter Pylori Eradication.
Helicobacter Infection
RecruitingObservational study
Feasibility and Performance of FFPE qPCR for Detection of Clarithromycin Resistance in Helicobacter Pylori
HELICOBACTER PYLORI INFECTIONS
RecruitingPhase 4
Efficacy and Safety of Linarazen Gluconate Capsules Combined With Amoxicillin (Dual-Drug Therapy) Versus Bismuth-Containing Quadruple Therapy for First-Line Eradication of Helicobacter Pylori Infection
HELICOBACTER PYLORI INFECTIONS
Not yet recruitingPhase 3
Efficacy and Safety of JP-1366-based Triple Therapy in Helicobacter Pylori-positive Subjects
H. Pylori Eradication Therapy
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Richard Adegbola, PhD, FRCPath principal investigator
Medical Research Council Unit, The Gambia
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Helicobacter Pylori, run by Medical Research Council Unit, The Gambia at 1 site in The Gambia.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 8 May 2015. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in The Gambia. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The degree of relatedness between bacterial isolates (time frame: 4 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 May 2015.